Denmark Financial Markets News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 8,
"returned": 6,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "efb84079-284d-4213-9dcf-3474ae785a91",
"title": "SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Acquisition - COWN, ECOM, SMBC, FMTX",
"description": "/PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the \"M&A Class Action Firm\"), a national...",
"keywords": "Monteverde & Associates PC",
"snippet": "NEW YORK, Oct. 2, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the \"M&A Class Action ...",
"url": "https://www.prnewswire.com:443/news-releases/shareholder-investigation-the-ma-class-action-firm-investigates-the-acquisition--cown-ecom-smbc-fmtx-301638465.html",
"image_url": "https://mma.prnewswire.com/media/443626/Monteverde_Associates_PC_Logo.jpg?p=facebook",
"language": "en",
"published_at": "2022-10-02T21:44:00.000000Z",
"source": "prnewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "NOVO-B.CO",
"name": "Novo Nordisk A/S",
"exchange": "CPH",
"exchange_long": "Nasdaq Copenhagen",
"country": "dk",
"type": "equity",
"industry": "Healthcare",
"match_score": 30.914745,
"sentiment_score": 0.5106,
"highlights": [
{
"highlight": "(Nasdaq: FMTX), relating to its proposed acquisition by <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>. Under the terms of the tender offer, FMTX shareholders are expected to receive $20.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/forma-therapeutics-holdings-inc. It is free and there is no cost or obligation to you.",
"sentiment": 0.5106,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "9cc1fcfb-8af6-41ce-b606-647a6422cf18",
"title": "Certified Advisor update",
"description": "Copenhagen, Oct. 02, 2022 -- Announcement no. 11-2022 Beierholm Corporate Finance P/S, which is approved as Certified Advisor by Nasdaq First North Growth Market Denmark, has... | October 2, 2022",
"keywords": "HYPEFACTORS A/S stock exchange, news, information, press release, 2022, announcement, beierholm, corporate, finance, which, is, approved, as, certified, advisor, by, nasdaq, first, north, growth, market | HYPE | DK0060989911",
"snippet": "Copenhagen, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Announcement no. 11-2022\n\n\n\n\n\n\n\n\n\nBeierholm Corporate Finance P/S, which is approved as Certified Advisor by Nasda...",
"url": "https://www.marketscreener.com/quote/stock/HYPEFACTORS-A-S-45568711/news/Certified-Advisor-update-41910233/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2022-10-02T21:16:01.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "HYPE.CO",
"name": "Hypefactors A/S",
"exchange": "CPH",
"exchange_long": "Nasdaq Copenhagen",
"country": "dk",
"type": "equity",
"industry": "Technology",
"match_score": 57.6601,
"sentiment_score": 0.4637,
"highlights": [
{
"highlight": ".\n\n-----\n\n\n\n\n\nAbout <em>Hypefactors</em> <em>A</em>/<em>S</em>\n\nHypefactors is an integrated AI powered Earned Media tech platform to support better media intelligence, reputation and trust management. Hypefactors combine data, analytics, technology and tools to provide a unified and easy-to-use experience.",
"sentiment": 0.9274,
"highlighted_in": "main_text"
},
{
"highlight": "ontjovet, Chairman of the Board: Tlf: +41 (0)78 922 33 0,\n\ne-mail: [email protected]\n\n\n\n\n\n<em>Hypefactors</em> <em>A</em>/<em>S</em>\n\nKronprinsessegade 8B\n\n1306 Copenhagen K\n\nDenmark\n\nwww.hypefactors.com\n\nCertified Adviser\n\nBeierholm Corporate Finance P/S\n\n?tergade 26B\n\n1100 K?havn K\n\nKim Harp?Jespersen, Partner, M +4552150243, email: [email protected]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "cfb24d84-bad7-4ba9-81b2-b86121014a29",
"title": "Certified Advisor update",
"description": "Copenhagen, Oct. 02, 2022 -- Announcement no. 11-2022 Beierholm Corporate Finance P/S, which is approved as Certified Advisor by Nasdaq First North Growth Market Denmark, has been... | October 2, 2022",
"keywords": "HYPEFACTORS A/S stock exchange, news, information, press release, 2022, announcement, beierholm, corporate, finance, which, is, approved, as, certified, advisor, by, nasdaq, first, north, growth, market, has | HYPE | DK0060989911",
"snippet": "Copenhagen, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Announcement no. 11-2022\n\n\n\n\n\n\n\n\n\nBeierholm Corporate Finance P/S, which is approved as Certified Advisor by Nasda...",
"url": "https://www.marketscreener.com/quote/stock/HYPEFACTORS-A-S-45568711/news/Certified-Advisor-update-41910264/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2022-10-02T21:15:31.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "HYPE.CO",
"name": "Hypefactors A/S",
"exchange": "CPH",
"exchange_long": "Nasdaq Copenhagen",
"country": "dk",
"type": "equity",
"industry": "Technology",
"match_score": 57.6601,
"sentiment_score": 0.4637,
"highlights": [
{
"highlight": ".\n\n-----\n\n\n\n\n\nAbout <em>Hypefactors</em> <em>A</em>/<em>S</em>\n\nHypefactors is an integrated AI powered Earned Media tech platform to support better media intelligence, reputation and trust management. Hypefactors combine data, analytics, technology and tools to provide a unified and easy-to-use experience.",
"sentiment": 0.9274,
"highlighted_in": "main_text"
},
{
"highlight": "ontjovet, Chairman of the Board: Tlf: +41 (0)78 922 33 0,\n\ne-mail: [email protected]\n\n\n\n\n\n<em>Hypefactors</em> <em>A</em>/<em>S</em>\n\nKronprinsessegade 8B\n\n1306 Copenhagen K\n\nDenmark\n\nwww.hypefactors.com\n\nCertified Adviser\n\nBeierholm Corporate Finance P/S\n\n?tergade 26B\n\n1100 K?havn K\n\nKim Harp?Jespersen, Partner, M +4552150243, email: [email protected]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "f8a4dd05-b8f8-4798-9815-35c409dc1829",
"title": "Certified Advisor update",
"description": "Copenhagen, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Announcement no. 11-2022 Beierholm Corporate Finance P/S, which is approved as Certified...",
"keywords": "Copenhagen Stock Exchange:HYPE, Hypefactors A/S",
"snippet": "Copenhagen, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Announcement no. 11-2022\n\n\n\n\n\n\n\n\n\nBeierholm Corporate Finance P/S, which is approved as Certified Advisor by Nasda...",
"url": "https://www.globenewswire.com/news-release/2022/10/02/2526427/0/en/Certified-Advisor-update.html",
"image_url": "https://www.globenewswire.com/Content/logo/favicon.ico",
"language": "en",
"published_at": "2022-10-02T21:15:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "HYPE.CO",
"name": "Hypefactors A/S",
"exchange": "CPH",
"exchange_long": "Nasdaq Copenhagen",
"country": "dk",
"type": "equity",
"industry": "Technology",
"match_score": 57.6601,
"sentiment_score": 0.6524,
"highlights": [
{
"highlight": ".\n\n-----\n\n\n\n\n\nAbout <em>Hypefactors</em> <em>A</em>/<em>S</em>\n\nHypefactors is an integrated AI powered Earned Media tech platform to support better media intelligence, reputation and trust management. Hypefactors combine data, analytics, technology and tools to provide a unified and easy-to-use experience.",
"sentiment": 0.9274,
"highlighted_in": "main_text"
},
{
"highlight": "For more information, please contact:\n\nCasper Janns, CEO: Tlf.: +45 20167481, e-mail: [email protected]\n\nPierre André Montjovet, Chairman of the Board: Tlf: +41 (0)78 922 33 0,\n\ne-mail: [email protected]\n\n\n\n\n\n<em>Hypefactors</em> <em>A</em>/<em>S</em>\n\nKronprinsessegade 8B\n\n1306 Copenhagen K\n\nDenmark\n\nwww.hypefactors.com\n\nCertified Adviser\n\nBeierholm Corporate Finance",
"sentiment": 0.3774,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "5affb8b1-2827-46cf-a232-c1c041afb4b1",
"title": "Global Peptide Synthesis Market Size To Reach USD 6.2 Bn By 2030 | CAGR 7.7%; Spherical Insights & Consulting",
"description": "The Global Peptide Synthesis Market Size was USD 4.3 Billion in 2021 and is projected to reach USD 6.2 Billion by 2030, exhibiting a CAGR of 7.7% during...",
"keywords": "SPHERICAL INSIGHTS LLP, Peptide Synthesis Market, Peptide Synthesis, Peptide Synthesis Market Size, Peptide Synthesis Market Share, Solid Phase, Liquid, SI",
"snippet": "New York, USA, Oct. 02, 2022 (GLOBE NEWSWIRE) -- The Global Peptide Synthesis Market Size was usd 4.3 billion in 2020 & is projected to reach usd 6.2 billion by...",
"url": "https://www.globenewswire.com/news-release/2022/10/02/2526413/0/en/Global-Peptide-Synthesis-Market-Size-To-Reach-USD-6-2-Bn-By-2030-CAGR-7-7-Spherical-Insights-Consulting.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/b27a94e8-407e-46ae-a5c2-47bb2a1c8a2e?size=1",
"language": "en",
"published_at": "2022-10-02T12:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "NOVO-B.CO",
"name": "Novo Nordisk A/S",
"exchange": "CPH",
"exchange_long": "Nasdaq Copenhagen",
"country": "dk",
"type": "equity",
"industry": "Healthcare",
"match_score": 31.454163,
"sentiment_score": 0.60935,
"highlights": [
{
"highlight": "., Syngene, Lonza, <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>, Bachem Holding AG, Gyros Protein Technologies, Creative Diagnostics, CEM Corporation amongst others.\n\nMajor companies are now focusing on inorganic tactics such as collaborations to expand their businesses, which is projected to enhance market growth over the forecast period.",
"sentiment": 0.7783,
"highlighted_in": "main_text"
},
{
"highlight": "Companies Covered: Genscript Biotech, Bachem Holding AG, Merck KGaA, Kaneka Corporation, Bachem Holdings, Biotage, CEM Corporation, Thermo Fisher, ProteoGenix, Creative Diagnostics, Polypeptide Group, Syngene International Ltd, PuroSynth, Lonza, MP Biomedicals, <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> and Others.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "9ace5a86-afc8-4f52-8ace-58216de935bf",
"title": "Great Valley Advisor Group Inc. Invests $240,000 in Novo Nordisk A/S (NYSE:NVO)",
"description": "Read Great Valley Advisor Group Inc. Invests $240,000 in Novo Nordisk A/S (NYSE:NVO) at ETF Daily News",
"keywords": "Novo Nordisk A/S, NYSE:NVO, NVO, Medical, SEC Filings, 13F, Hedge Fund Holdings, Institutional Investor Holdings",
"snippet": "Great Valley Advisor Group Inc. acquired a new position in Novo Nordisk A/S (NYSE:NVO – Get Rating) in the second quarter, according to its most recent Form 1...",
"url": "https://www.etfdailynews.com/2022/10/02/great-valley-advisor-group-inc-invests-240000-in-novo-nordisk-a-s-nysenvo/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/novo-nordisk-logo.jpg&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-02T09:14:56.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "NOVO-B.CO",
"name": "Novo Nordisk A/S",
"exchange": "CPH",
"exchange_long": "Nasdaq Copenhagen",
"country": "dk",
"type": "equity",
"industry": "Healthcare",
"match_score": 150.44775,
"sentiment_score": 0.134482,
"highlights": [
{
"highlight": "Finally, WCM Investment Management LLC grew its stake in <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> by 14.7% during the first quarter.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Get <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> alerts:\n\nAnalyst Ratings Changes\n\nSeveral research firms recently weighed in on NVO. Exane BNP Paribas raised shares of <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> from an “underperform” rating to a “neutral” rating and set a 750.00 target price for the company in a research note on Monday, June 27th.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Oddo Bhf upgraded shares of <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> from a “neutral” rating to an “outperform” rating in a research report on Thursday. UBS Group lowered shares of <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> from a “neutral” rating to a “sell” rating in a research report on Tuesday, June 28th.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Morgan Stanley upgraded shares of <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> from an “equal weight” rating to an “overweight” rating in a research report on Friday, July 15th.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> Price Performance\n\n<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> stock opened at $99.63 on Friday. The firm has a 50-day moving average price of $105.64 and a 200-day moving average price of $109.10. The firm has a market capitalization of $225.46 billion, a PE ratio of 29.74, a price-to-earnings-growth ratio of 1.79 and a beta of 0.47.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> has a 12-month low of $91.51 and a 12-month high of $122.16.\n\n<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> (NYSE:NVO – Get Rating) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.87 by ($0.03).",
"sentiment": -0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> had a return on equity of 72.10% and a net margin of 32.14%. As a group, equities research analysts forecast that <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> will post 3.4 EPS for the current year.\n\n<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> Cuts Dividend\n\nThe business also recently declared a semi-annual dividend, which was paid on Tuesday, August 23rd.",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> Profile\n\n(Get Rating)\n\n<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "Visit HoldingsChannel.com to get the latest 13F filings and insider trades for <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> (NYSE:NVO – Get Rating).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Receive News & Ratings for <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "Invests $240,000 in <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> (NYSE:NVO)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "c07204af-d7c0-4109-879a-fd8d86539af4",
"title": "Genmab A/S (NASDAQ:GMAB) Shares Sold by DAVENPORT & Co LLC",
"description": "Read Genmab A/S (NASDAQ:GMAB) Shares Sold by DAVENPORT & Co LLC at ETF Daily News",
"keywords": "Genmab A/S, NASDAQ:GMAB, GMAB, Medical, SEC Filings, 13F, Hedge Fund Holdings, Institutional Investor Holdings",
"snippet": "DAVENPORT & Co LLC trimmed its position in shares of Genmab A/S (NASDAQ:GMAB – Get Rating) by 6.6% during the second quarter, HoldingsChannel reports. The fun...",
"url": "https://www.etfdailynews.com/2022/10/02/genmab-a-s-nasdaqgmab-shares-sold-by-davenport-co-llc/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/genmab-as-logo.png&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-02T08:52:49.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "GMAB.CO",
"name": "Genmab A/S",
"exchange": "CPH",
"exchange_long": "Nasdaq Copenhagen",
"country": "dk",
"type": "equity",
"industry": "Healthcare",
"match_score": 133.25008,
"sentiment_score": 0.255809,
"highlights": [
{
"highlight": "DAVENPORT & Co LLC’s holdings in <em>Genmab</em> <em>A</em>/<em>S</em> were worth $367,000 as of its most recent filing with the Securities & Exchange Commission.\n\nA number of other institutional investors and hedge funds have also made changes to their positions in GMAB. Veriti Management LLC grew its position in <em>Genmab</em> <em>A</em>/<em>S</em> by 8.0% during the second quarter.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Private Advisor Group LLC grew its position in <em>Genmab</em> <em>A</em>/<em>S</em> by 2.0% during the second quarter. Private Advisor Group LLC now owns 20,522 shares of the company’s stock worth $666,000 after buying an additional 403 shares during the period. Cim LLC grew its position in <em>Genmab</em> <em>A</em>/<em>S</em> by 7.4% during the second quarter.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "Finally, Quantamental Technologies LLC acquired a new position in <em>Genmab</em> <em>A</em>/<em>S</em> during the first quarter worth about $451,000. 5.51% of the stock is currently owned by institutional investors and hedge funds.\n\nGet <em>Genmab</em> <em>A</em>/<em>S</em> alerts:\n\n<em>Genmab</em> <em>A</em>/<em>S</em> Stock Performance\n\nShares of GMAB opened at $32.13 on Friday.",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Genmab</em> <em>A</em>/<em>S</em> has a 1 year low of $26.19 and a 1 year high of $47.28.\n\nAnalyst Upgrades and Downgrades\n\n<em>Genmab</em> <em>A</em>/<em>S</em> ( NASDAQ:GMAB Get Rating ) last announced its quarterly earnings data on Wednesday, August 10th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.20.",
"sentiment": -0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Genmab</em> <em>A</em>/<em>S</em> had a net margin of 38.42% and a return on equity of 17.12%. Equities analysts expect that <em>Genmab</em> <em>A</em>/<em>S</em> will post 1.02 EPS for the current fiscal year.\n\nSeveral research analysts have weighed in on GMAB shares.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "SVB Leerink upped their target price on shares of <em>Genmab</em> <em>A</em>/<em>S</em> from $30.00 to $31.00 and gave the stock a “market perform” rating in a research report on Thursday, August 11th. TheStreet raised shares of <em>Genmab</em> <em>A</em>/<em>S</em> from a “c+” rating to a “b” rating in a report on Wednesday, August 31st.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "BMO Capital Markets began coverage on shares of <em>Genmab</em> <em>A</em>/<em>S</em> in a report on Thursday, June 23rd. They issued a “market perform” rating and a $34.73 price target on the stock. Morgan Stanley upped their price target on shares of <em>Genmab</em> <em>A</em>/<em>S</em> from $29.00 to $31.00 and gave the company an “underweight” rating in a report on Monday, August 15th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Based on data from MarketBeat.com, <em>Genmab</em> <em>A</em>/<em>S</em> currently has a consensus rating of “Hold” and an average price target of $547.62.\n\n<em>Genmab</em> <em>A</em>/<em>S</em> Company Profile\n\n(Get Rating)\n\n<em>Genmab</em> <em>A</em>/<em>S</em> develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.",
"sentiment": -0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Visit HoldingsChannel.com to get the latest 13F filings and insider trades for <em>Genmab</em> <em>A</em>/<em>S</em> (NASDAQ:GMAB – Get Rating).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Receive News & Ratings for <em>Genmab</em> <em>A</em>/<em>S</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>Genmab</em> <em>A</em>/<em>S</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Genmab</em> <em>A</em>/<em>S</em> (NASDAQ:GMAB) Shares Sold by DAVENPORT & Co LLC",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "9575837a-e32a-4f75-8772-ef308fc10678",
"title": "Genmab A/S (NASDAQ:GMAB) Stake Lessened by Bank of America Corp DE",
"description": "Read Genmab A/S (NASDAQ:GMAB) Stake Lessened by Bank of America Corp DE at ETF Daily News",
"keywords": "Genmab A/S, NASDAQ:GMAB, GMAB, Medical, SEC Filings, 13F, Hedge Fund Holdings, Institutional Investor Holdings",
"snippet": "Bank of America Corp DE cut its stake in Genmab A/S (NASDAQ:GMAB – Get Rating) by 1.3% in the 1st quarter, according to its most recent Form 13F filing with t...",
"url": "https://www.etfdailynews.com/2022/10/02/genmab-a-s-nasdaqgmab-stake-lessened-by-bank-of-america-corp-de/",
"image_url": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/genmab-as-logo.png&w=240&h=240&zc=2",
"language": "en",
"published_at": "2022-10-02T08:08:46.000000Z",
"source": "etfdailynews.com",
"relevance_score": null,
"entities": [
{
"symbol": "GMAB.CO",
"name": "Genmab A/S",
"exchange": "CPH",
"exchange_long": "Nasdaq Copenhagen",
"country": "dk",
"type": "equity",
"industry": "Healthcare",
"match_score": 124.3871,
"sentiment_score": 0.239645,
"highlights": [
{
"highlight": "Bank of America Corp DE’s holdings in <em>Genmab</em> <em>A</em>/<em>S</em> were worth $30,757,000 at the end of the most recent reporting period.\n\nOther large investors have also recently added to or reduced their stakes in the company. Captrust Financial Advisors boosted its holdings in <em>Genmab</em> <em>A</em>/<em>S</em> by 62.0% during the first quarter.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "LBA bought a new stake in <em>Genmab</em> <em>A</em>/<em>S</em> during the fourth quarter worth approximately $219,000. Seven Eight Capital LP bought a new stake in <em>Genmab</em> <em>A</em>/<em>S</em> during the first quarter worth approximately $215,000. SG Americas Securities LLC boosted its holdings in <em>Genmab</em> <em>A</em>/<em>S</em> by 9.3% during the first quarter.",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "Get <em>Genmab</em> <em>A</em>/<em>S</em> alerts:\n\n<em>Genmab</em> <em>A</em>/<em>S</em> Trading Up 0.6 %\n\nNASDAQ GMAB opened at $32.13 on Friday. <em>Genmab</em> <em>A</em>/<em>S</em> has a 1-year low of $26.19 and a 1-year high of $47.28. The company has a market capitalization of $21.15 billion, a PE ratio of 35.70, a price-to-earnings-growth ratio of 1.19 and a beta of 0.85.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Analyst Upgrades and Downgrades\n\n<em>Genmab</em> <em>A</em>/<em>S</em> ( NASDAQ:GMAB Get Rating ) last posted its quarterly earnings results on Wednesday, August 10th. The company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.20. <em>Genmab</em> <em>A</em>/<em>S</em> had a net margin of 38.42% and a return on equity of 17.12%.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "As a group, analysts predict that <em>Genmab</em> <em>A</em>/<em>S</em> will post 1.02 EPS for the current year.\n\nA number of analysts recently weighed in on GMAB shares. BMO Capital Markets started coverage on shares of <em>Genmab</em> <em>A</em>/<em>S</em> in a report on Thursday, June 23rd. They set a “market perform” rating and a $34.73 target price for the company.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "TheStreet upgraded shares of <em>Genmab</em> <em>A</em>/<em>S</em> from a “c+” rating to a “b” rating in a research report on Wednesday, August 31st. SVB Leerink upped their price target on shares of <em>Genmab</em> <em>A</em>/<em>S</em> from $30.00 to $31.00 and gave the company a “market perform” rating in a research report on Thursday, August 11th.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "HC Wainwright increased their target price on <em>Genmab</em> <em>A</em>/<em>S</em> from $49.00 to $51.00 and gave the company a “buy” rating in a report on Monday, August 22nd. Finally, Morgan Stanley lifted their price target on <em>Genmab</em> <em>A</em>/<em>S</em> from $29.00 to $31.00 and gave the company an “underweight” rating in a report on Monday, August 15th.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Genmab</em> <em>A</em>/<em>S</em>\n\n(Get Rating)\n\n<em>Genmab</em> <em>A</em>/<em>S</em> develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.",
"sentiment": -0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Visit HoldingsChannel.com to get the latest 13F filings and insider trades for <em>Genmab</em> <em>A</em>/<em>S</em> (NASDAQ:GMAB – Get Rating).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Receive News & Ratings for <em>Genmab</em> <em>A</em>/<em>S</em> Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for <em>Genmab</em> <em>A</em>/<em>S</em> and related companies with MarketBeat.com's FREE daily email newsletter.",
"sentiment": 0.6166,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Genmab</em> <em>A</em>/<em>S</em> (NASDAQ:GMAB) Stake Lessened by Bank of America Corp DE",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "dk",
"total_documents": 8,
"sentiment_avg": 0.41621075198054314
}
]
}
Other details
Exchanges included in this country
- CPH
- 823